Back to news

Mesoblast Wins Deloitte Tech Fast 50 Leadership & Enterprise Growth Award

Globe Newswire•19/11/2026•18:51 ET
2

Key Highlights

  • ➤Mesoblast (MESO) wins Deloitte Technology Fast 50 Leadership & Enterprise Growth Award
  • ➤RYONCIL launch establishes Mesoblast’s commercial-stage biotechnology foundation
  • ➤RYONCIL is FDA-approved for pediatric steroid-refractory acute graft versus host disease
  • ➤Mesoblast’s pipeline targets adult SR-aGvHD, inflammatory bowel disease, heart failure and back pain

Expert Statements

Silviu Itescu, Chief Executive of Mesoblast

“We are pleased to receive this award from Deloitte which recognizes Mesoblast's leadership excellence across innovation and scalability in the healthcare industry.”

Silviu Itescu, Chief Executive of Mesoblast

“The successful launch of RYONCIL has established a strong commercial foundation for Mesoblast and has enabled patients to access a life changing product.”

Silviu Itescu, Chief Executive of Mesoblast

“We are focused on building on that foundation, progressing our broader portfolio and delivering sustainable growth and long-term value for our shareholders.”

NEW YORK, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received the Leadership & Enterprise Growth Award at the Deloitte Technology Fast 50 Australia Awards which recognizes Australia’s fastest-growing technology companies and the founders, innovators and leaders shaping the future of the sector.

The award recognizes Mesoblast’s successful evolution to a commercial-stage biotechnology company following its U.S. launch of Ryoncil(®) (remestemcel-L-rknd), the first mesenchymal stromal cell therapy approved by the U.S. Food and Drug Administration (FDA).(1)

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in